Mark Lewis, Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, shared, Kate Sears’s, Global Marketing Director at Open Medicine, post on X, adding:
“One of the most transformative conferences I’ve ever attended – the best part was bringing legitimate hope back to patients in clinic this week.”
Quoting Kate Sears’s post:
“Announcing the Top Posts of ASCO26!
- Mark Lewis on RASolute 302 and daraxonrasib for pancreatic cancer.
- Paolo Tarantino on PANKU-Breast02 for pretreated mTNBC.
- Ashish M. Kamat on durvalumab and BCG for HR non-muscle invasive bladder cancer.
- Toni Choueiri on TALAPRO-3 in HRR-deficient metastatic prostate cancer.
- Vincent Rajkumar on Majestec-9 in relapsed multiple myeloma.
- Nicholas Hornstein on KEYNOTE-942 in HR resected melanoma.
- Anil Tibdewal on managing brain mets in EGFR/ALK mutant NSCLC.
- Nina Niu Sanford on Neo-CRAG in locally advanced gastric cancer.
- Yüksel Ürün on RADICAL in RCC with bone metastases.
- Arndt Vogel on IMbrave251 in locally advanced HCC.
- Taro Yamanaka on ADCs in recurrent/metastatic cervical cancer.”
Other articles featuring Mark Lewis and Kate Sears on OncoDaily.